Cite
HARVARD Citation
Coates, L. et al. (2023). Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD open. 9 (2), p. . [Online].